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ARTICLE
A haemagglutination test for rapid detection of
antibodies to SARS-CoV-2
Alain Townsend 1,2✉, Pramila Rijal1,2, Julie Xiao1, Tiong Kit Tan 1, Kuan-Ying A. Huang 3,4,
Lisa Schimanski1,2, Jiandong Huo5, Nimesh Gupta 6, Rolle Rahikainen 7, Philippa C. Matthews8,9,
Derrick Crook8,10,11, Sarah Hoosdally9,11, Susanna Dunachie 9,12, Eleanor Barnes 10, Teresa Street10,11,
Christopher P. Conlon 10, John Frater 10, Carolina V. Arancibia-Cárcamo10, Justine Rudkin13,
Nicole Stoesser 8,10, Fredrik Karpe11,14, Matthew Neville 14, Rutger Ploeg 15, Marta Oliveira15,
David J. Roberts16,17, Abigail A. Lamikanra16, Hoi Pat Tsang16, Abbie Bown18, Richard Vipond18,
Alexander J. Mentzer 19, Julian C. Knight 2,11,19, Andrew J. Kwok 19, Gavin R. Screaton 19,20,
Juthathip Mongkolsapaya 2,19,21, Wanwisa Dejnirattisai19, Piyada Supasa19, Paul Klenerman9,
Christina Dold22,23, J. Kenneth Baillie 24, Shona C. Moore 25, Peter J. M. Openshaw 26,
Malcolm G. Semple 25, Lance C. W. Turtle 25, Mark Ainsworth12, Alice Allcock19, Sally Beer 12,
Sagida Bibi22, Donal Skelly 12, Lizzy Stafford12, Katie Jeffrey 12, Denise O’Donnell12, Elizabeth Clutterbuck22,
Alexis Espinosa12, Maria Mendoza12, Dominique Georgiou12, Teresa Lockett12, Jose Martinez12, Elena Perez12,
Veronica Gallardo Sanchez12, Giuseppe Scozzafava12, Alberto Sobrinodiaz12, Hannah Thraves12 &
Etienne Joly 27✉
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of ser-
oconversion in populations, and for seeking evidence for a level of antibody that may be
protective against COVID-19 disease. Several high-performance commercial tests have been
described, but these require centralised laboratory facilities that are comparatively expensive,
and therefore not available universally. Red cell agglutination tests do not require special
equipment, are read by eye, have short development times, low cost and can be applied at the
Point of Care. Here we describe a quantitative Haemagglutination test (HAT) for the
detection of antibodies to the receptor binding domain of the SARS-CoV-2 spike protein. The
HAT has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR
diagnosed infection. We will supply aliquots of the test reagent sufficient for ten thousand
test wells free of charge to qualified research groups anywhere in the world.
https://doi.org/10.1038/s41467-021-22045-y OPEN
A full list of author affiliations appears at the end of the paper.









Red cell agglutination tests have a distinguished history.Since Landsteiner’s classic observations in 19011 (Englishtranslation), they have been used for the determination of
blood groups2, detection of influenza viruses,3 and in a wide
variety of applications championed by Prof. Robin Coombs for
the detection of specific antibodies or antigens4 (reviewed by
ref. 5). They have the great advantage of being simple, inexpen-
sive, can be read by eye, and do not require sophisticated tech-
nology for their application. In the recent era, the linkage of an
antigen to the red cell surface has become easier with the possi-
bility of fusing a protein antigen sequence with that of a single
domain antibody or nanobody specific for a molecule on the red
cell surface (discussed in ref. 6).
We have applied this concept to provide a simple haemagglu-
tination test (“HAT”) for the detection of antibodies to the
receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
The RBD is a motile subdomain at the tip of the SARS-CoV-2
spike protein that is responsible for binding the virus to its ACE2
receptor. The RBD of betacoronaviruses folds independently of
the rest of the spike protein7–10. This useful property provides an
Achilles’ heel for the virus and allows many potential applications
in vaccine design11–16 and serology17–19, see also www.gov.uk/
government/publications/COVID-19-laboratory-evaluations-of-
serological-assays. The majority of neutralising antibodies bind to
the RBD18,20, and the level of antibody to the RBD detected in
ELISA correlates with that of neutralising antibodies17,18,21,22. We
reasoned therefore that a widely applicable and inexpensive test
for antibodies to the RBD would be useful for research in settings
where high throughput assays were not available.
In order to link the SARS-CoV-2 RBD to red cells, we selected
the single domain antibody (nanobody) IH46, specific for a
conserved epitope on glycophorin A. Glycophorin A is expressed
at up to 106 copies per red cell. The IH4 nanobody has previously
been linked to HIV p24 to provide a monomeric reagent that
bound p24 to the red cell surface. Antibodies to p24 present in
serum crosslinked the p24 and agglutinated the red cells6. We
have adapted this approach for detection of antibodies to SARS-
CoV-2 by linking the RBD of the SARS-CoV-2 spike protein to
IH4 via a short (GSG)2 linker to produce the fusion protein IH4-
RBD-6H (Fig. 1). Since we embarked on this project, another
group has described preliminary results with an approach similar
to ours, but using a fusion of the RBD to an scFv against the H
antigen to coat red blood cells with the SARS-2 RBD23.
Results
Production of the IH4-RBD Reagent. The IH4-RBD sequence
(Fig. 1B and Supplementary Note) was codon optimised and
expressed in Expi293F cells in a standard expression vector
(available on request). One advantage of this mode of production
compared to bacterially produced protein as used by Habib et al.
is that the reagent will carry the glycosylation moieties found in
humans, which may play a role in the antigenicity of the RBD24.
The protein (with a 6xHis tag at the C-terminus for purification)
was purified by Ni-NTA chromatography which yielded ~160
mg/L. We later had 1 g of the protein synthesised commercially
by Absolute Antibody, Oxford. The IH4-RBD protein ran as
single band at ~40 kDa on SDS-PAGE (Fig. 1C).
Establishment of the HAT with monoclonal antibodies to the
RBD. One purpose envisaged for the HAT is for use as an
inexpensive point of care test for detection of antibodies in
capillary blood samples obtained by a “finger prick”. We therefore
wished to employ human red cells as indicators without the need
for cell separation or washes, to mimic this setting. The use of V-
bottom microtiter plates to perform simplified hemagglutination
tests was first described over 50 years ago25. In preliminary tests,
we observed that 50 µL of whole blood (K2EDTA sample) diluted
1:40 in phosphate-buffered saline (PBS), placed in V-bottomed
wells of a standard 96-well plate, settled in 1 h to form a button of
red cells at the bottom of the well. The normal haematocrit of
blood is ~40% vol/vol, so this dilution provides ~1% red cells. If
the plate was then tilted, the red cell button flowed to form a
“teardrop” in ~30 s (for example, Fig. 2A, bottom row).
If serum or plasma samples are to be tested, a standard collection
of 10mL of type O Rh-negative (O−ve) blood into a K2EDTA tube
will thus provide sufficient red cells for 8000 test wells.
A well-characterised monoclonal antibody to the RBD,
CR302226,27 added to the red cells at between 0.5 and 32 ng/well
in 50 µL, did not agglutinate the cells on its own (Fig. 2A, row 8). The
addition of the IH4-RBD reagent at between 12.5 and 800 ng/well (in
50 µL PBS) induced a concentration dependent agglutination of the
red cells, detected by the formation of a visible mat or plug of
agglutinated cells, and the loss of teardrop formation on tilting the
plate (Fig. 2A). From repeated trials of this experiment, we
established that a standard addition of 100 ng/well of the IH4-RBD
developer (50 µL of a stock solution of 2 µg/mL in PBS) induced
agglutination of 50 µL of 1:40 human red cells in the presence of as
little as 2 ng/well of the CR3022 monoclonal antibody. The
standardised protocol used for the subsequent tests were thus
performed in 100 or 150 µL final volume, containing 100 ng of the
IH4-RBD developer, and 50 µL 1:40 whole blood (~1% v/v red cells
~0.5 µL packed red cells per reaction). After 60min incubation
at room temperature, we routinely photographed the plates after the
30 s tilt for examination and reading.
The requirement for 100 ng of the IH4-RBD developer per test
well means that the gram of IH4-RBD protein we have had
synthesised is sufficient for 10 million test wells at a cost of ~0.27
UK pence per test.
Having established a standard addition of 100 ng/well of the
IH4-RBD reagent, we screened a set of 13 human monoclonal
antibodies, two divalent nanobodies, divalent ACE2-Fc, and a
murine monoclonal antibody to the 6H tag, which are known to
bind to the RBD24,28–31. These reagents bind to at least four
independent sites on the RBD, and some are strongly neutralising
and capable of profound ACE2 blockade28,29. Overall, 13 of the
15 divalent molecules agglutinated red cells and titrated in the
HAT to an endpoint between 2 and 125 ng/well, after addition of
100 ng IH4-RBD (Fig. 2B and Supplementary Table 1). One mono-
clonal antibody, FD-5D 28 and one divalent nanobody, VHH72-
Fc31, failed to agglutinate red cells in the presence of the IH4-RBD
reagent. However, if a monoclonal antibody to human IgG was
added to the reaction (50 µL of mouse anti-human IgG, Sigma
Clone GG-5 1:100), these molecules specifically agglutinated the
red cells (Supplementary Fig. 1A, B). This result, analogous to the
“indirect” Coombs test4,5, suggested that these two molecules had
bound to the RBD associated with the red cells but failed to
crosslink to RBDs on neighbouring red cells. However, these could
be crosslinked by the anti-IgG reagent. Monoclonal antibodies to
other regions of the spike protein (EW-9B, EW-9C,and FJ-1C)
failed to agglutinate red cells (Fig. 2B, Supplementary Table 1).
Finally, we looked at the effect of a divalent ACE2-Fc molecule
constructed by fusing the peptidase domain of ACE2 (amino acids
19–615) to the hinge and Fc region of human IgG1 (described in
ref. 29). ACE2-Fc agglutinated red cells strongly in the presence of
100 ng/well of the IH4-RBD developer, titrating to ~4 ng/well
(Fig. 2B, rows 7 and 8).
In summary, these results showed that all of the known
epitopes bound by characterised monoclonal antibodies were
displayed by the IH4-RBD reagent, as well as the ACE2 binding
site, and could mediate agglutination by specific antibodies,
divalent nanobodies, or ACE2-Fc.
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For clinical testing, samples can be supplied as serum or
plasma. We therefore compared the effect of serum, K2EDTA, or
heparin plasma on the HAT titration endpoints by diluting
monoclonal antibodies to each of the four known binding sites on
the RBD20 (FI-3A class 1, C121 class 2, FD-11A class 3, and
CR3022 class 4) in serum or plasmas. The titration endpoints
obtained in dilutions of serum or plasmas, maintained at 1:20
throughout, did not differ from each other or from the MAbs
diluted in PBS (Supplementary Fig. 5). We conclude that the
plasma or serum origin of samples is unlikely to influence
sensitivity in the haemagglutination assay.
Agglutination by plasma from donors convalescing from
COVID-19. These experiments established the conditions for
detection of haemagglutination by monoclonal antibodies to the
Fig. 1 Haemagglutination test (HAT) for detection of antibodies to SARS-CoV-2 receptor binding domain. A Concept of the HAT. B Sequence of VHH
(IH4)-RBD fusion protein. Residues underlined are encoded by cloning sites AgeI (TG) and SalI (AST). The codon-optimised cDNA sequence is shown
in Supplementary Information. C SDS-PAGE gel of purified VHH(IH4)-RBD proteins. Three micrograms of protein were run on 4–12% Bolt Bis-Tris under
reducing conditions. 1: IH4-RBD produced in house in Expi293F cells. 2: IH4-RBD produced by Absolute Antibody, Oxford, in HEK293 cells. This was done
twice with similar results.
Fig. 2 Haemagglutination with human monoclonal antibodies or nanobodies to the SARS-CoV-2 RBD. A Titration of IH4-RBD and monoclonal antibody
CR3022 to RBD. Doubling dilutions of CR3022 and IH4-RBD were prepared in separate plates. 50 µL red cells (O−ve whole blood diluted 1:40 in PBS) were
added to the CR3022 plate, followed by transfer of 50 µL titrated IH4-RBD. From this titration, 100 ng/well of IH4-RBD was chosen for detection. Similar
results were obtained in five other experiments, performed with three separate batches of IH4-RBD. B Detection of other anti-RBD monoclonal antibodies
and ACE2-Fc. Doubling dilutions of monoclonal antibodies were prepared in duplicate in 50 µL PBS (from a stock solution of 20 µg/mL) from left to right,
50 µL of 1:40 O−ve red cells were added, followed by 50 µL of IH4-RBD (2 µg/mL in PBS). The endpoint was defined as the last dilution without teardrop
formation on tilting the plate for ~30 s. The binding sites for CR3022, EY6A, and ACE2 on RBD have been defined8,10,27,30. EW-9B and EW-9C are
monoclonal antibodies against non-RBD epitopes on the spike protein 28. ACE2-Fc has been described in ref. 28. Similar results were obtained in two other
titration experiments.
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RBD, in particular the optimum concentration of IH4-RBD of
100 ng/well. We then proceeded to look for haemagglutination by
characterised plasma from COVID-19 convalescent donors. In
the first trial, we tested 18 plasma samples from patients with
mostly mild illness, which had been characterised with a quan-
titative ELISA to detect antibodies to the RBD32. For these
experiments we used fresh O−ve blood (K2EDTA sample)
diluted to 1:40 as a source of red cells to avoid agglutination by
natural agglutinins in the plasma. Plasmas were titrated by dou-
bling dilution from 1:20 in 50 µL, then 50 µL of 1:40 O−ve red
cells were added, followed by addition of 100 ng of the IH4-RBD
in 50 µL PBS. After 1 h incubation, plates were tilted for ~30 s,
photographed, and read. The titre of agglutination was assessed
by complete loss of teardrop formation by the red cells, any
formation of a teardrop was regarded as negative. Figure 3A
shows that the HAT titre matched the RBD ELISA results. Four
samples were scored as negative in both assays. The remaining
results showed that in general the HAT titre increased with the
ELISA endpoint titre. One sample gave a positive titre of 1:320 in
the HAT but was negative in ELISA (indicated with an arrow).
We investigated this sample with a developer composed of the
IH4 nanobody without the RBD component, which revealed that
agglutination was RBD dependent (Supplementary Fig. 6). This
sample was also positive at 1:1123 in an ELISA for full length
spike protein (not shown)32, which suggests that the antibodies
contained in this serum recognised epitope(s) present on the RBD
exposed in the HAT, but not on the RBD in the RBD ELISA
reference test. The highest titre detected in these samples by the
HAT was 1:1280 (Fig. 3B).
We next compared red cell agglutination detected by eye, with
detection of binding of monoclonal and serum antibodies to the
RBD by FACS analysis. Antibody binding, as detected by indirect
immunofluorescence, titrated commensurately with the loss of
teardrop formation by the settled red cells, detected by eye
(Fig. 3C). Note that full loss of teardrop, our defined objective
endpoint, occurred well before saturation of the IH4-RBD
labelled red cells with either monoclonal or polyclonal antibodies
to the RBD.
Finally, we assessed the degree of variability in the HAT
titration of serum/plasma samples introduced by sourcing O−ve
indicator red cells from different donors. Four monoclonal
antibodies to the four known binding sites on the RBD20 and four
Fig. 3 Titration of antibodies in the agglutination assay. A Eighteen plasma samples from mild cases were compared for titration in the HAT with 1:40 O
−ve whole blood from a seronegative donor and endpoint titre in an RBD ELISA32. Four samples were negative in both assays. The data point marked with
an arrow on the graph (plasma 2 on the plate, Fig. 3B) was checked with a reagent composed of IH4 without RBD and shown to be dependent on
antibodies to the RBD. This sample did score positive for antibodies to full length spike in an ELISA (endpoint titre 1:1123). These results were confirmed in a
repeat assay. B An example of titration: positive agglutination endpoints (loss of teardrop) are marked with a black solid-line circle, partial teardrops are
marked with a dotted-line circle. C Titration of mAb CR3022 and a high titre serum from a COVID-19 patient show that agglutination in the HAT detected
by eye correlates with antibody binding to RBCs, as revealed by FACS analysis. Standard HAT titration was performed by double dilutions of RBC
suspension containing 1 µg/mL of the IH4-RBD reagent, bar the first and last well. After the HAT assay, the RBCs were stained for FACS analysis by
performing three washes before incubation for 60min at 4 °C with FITC-labelled goat–anti-human IgG. RBCs were then washed twice before analysis by
flow cytometry. Green numbers in the upper right corners of the histograms correspond to the geometric mean fluorescence intensity. Original graphs are
provided as Supplementary Fig. 4. Similar results were obtained in three other experiments.
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sera (selected for high, middle, low, and negative titres) were
titrated in quadruplicate on red cells from three donors. The
titration endpoints did not vary by more than +/−1 doubling
dilution between donors. Disagreements between scorers were
detected in 5/108 measurements, all within one doubling dilution
of each other (Supplementary Tables 3 and 4).
This small amount of variation in endpoints between O−ve red
cells sourced from different donors can be controlled by including
defined standard sera or monoclonal antibodies in all batches of
assays. The WHO/NIBSC (UK) international secondary standard
serum 20/130 (recently available from NIBSC UK), which titrates
to 1:1280 in the HAT (Supplementary Fig. 3), can be used for
calibration of assay endpoints within and between laboratories,
and for calibration of local control sera.
These preliminary results showed that the HAT could detect
antibodies to the RBD in serum or plasma samples from
convalescent patients in a similar manner to an ELISA test, but
were not sufficient to establish the sensitivity and specificity of
the HAT.
Sensitivity and specificity of the HAT. To formally assess the
sensitivity and specificity of the HAT, we collected a set of 98
“positive” plasma samples from donors diagnosed with COVID-
19 by reverse transcriptase polymerase chain reaction (RT-PCR)
at least 28 days prior to sample collection (NHS Blood and
Transplant), and 199 “negative” serum samples from healthy
donors from the pre COVID-19 era (Oxford Biobank). The
samples were randomised before plating. The test wells were
arranged in duplicate to contain serum/plasma at 1:40 dilution,
and 1:40 O−ve red cells in 50 µL. One hundred nanograms of
IH4-RBD in 50 µL PBS was added to one well of the pair, 50 µL of
PBS to the other (as a negative control). The negative control is
important because in rare cases, particularly in donors who may
have received blood transfusions, the sample may contain anti-
bodies to non-ABO or Rhesus D antigens. After development, the
plates were photographed, and read by two independent masked
observers. Complete loss of teardrop was scored as positive, any
flow in the teardrop as negative. These rules were established
before setting up the tests. Disagreements (2.3% overall) were
resolved by accepting the weaker interpretation—i.e., if one
observer scored positive but the other negative, the well was
scored as negative. Having completed the scoring the columns of
samples were re-randomised and the test and scoring repeated.
Examples of test wells and scoring are shown in Fig. 4. The red
cells in all of the negative control (PBS) wells formed a clear
teardrop. Red cells in positive wells (indicated with a solid ring)
settled either into a mat or a button that failed to form any
teardrop on tilting for 30 s. Occasional wells (15 of 297) formed a
“partial” teardrop (shown by a dashed ring). These were scored as
negative by prior agreement.
With these rules in place, we obtained in the first run
sensitivity 88%, specificity 99% and in the second run sensitivity
93%, specificity 99% (Fig. 4). The Siemens Atellica Chemilumi-
nescence assay for detection of IgG antibodies to the RBD was
run in parallel on 293 of these 297 samples and gave sensitivity
100%, specificity 100% for this sample set.
We decided prior to this formal assessment to score wells with
partial teardrop formation as negative, as these wells tended to give
rise to disagreements between scorers and were associated with very
low-level of staining in the FACS analysis (Fig. 3C). Overall, 15 of
297 wells gave a partial teardrop. Six of these fifteen were from PCR
−ve donors and scored negative on the Siemens assay, and nine out
of sixteen were from PCR+ve donors and were Siemens positive. If
partial teardrops were scored as positive, the sensitivity of the two
assays increased to 97 and 99% (from 88 and 93%), but specificity
was reduced to 96 and 98% (from 99%). This small loss of
specificity would be unacceptable in serosurveys where the expected
prevalence of previous SARS-CoV-2 infection was low.
HAT in the hospital setting. We next assessed the HAT in the
setting of patients recently admitted to hospital (the first 5 days)
through access to the COMBAT collection of samples (see
“Methods”). This set comprised 153 plasma samples from donors
diagnosed with COVID-19 by PCR, with clinical syndromes
classified as « Critical », « Severe », « Mild », and «PCR positive
Health Care Workers ». Seventy-nine control plasma samples
donated in the pre COVID-19 era were obtained either from
patients with bacterial sepsis (54 samples) or healthy volunteers
(25 samples). Samples were titrated in 11 doubling dilutions of
50 µL from 1:40–1:40,096 (columns 1–11). Column 12 contained
50 µL PBS as a negative control. Fifty microlitres of 1:40 O−ve
whole blood was added, followed by 50 µL of 2 µg/mL IH4-RBD
(100 ng/well). In parallel, all of the 153 samples from PCR posi-
tive donors were assessed by the Siemens Atellica Chemilumi-
nescence test for antibodies to the RBD of the spike protein. The
HAT scores (as the number of doubling dilutions of the sample
required to reach the endpoint of complete loss of teardrop), and
representative agglutination results are shown in Fig. 5A. In
Fig. 5B, the HAT scores are plotted with their related Siemens
test scores.
None of the seventy-nine negative control samples scored as
positive in the HAT at a dilution of 1:40, thus providing 100%
specificity in this set of samples. The HAT detected 131/153 (86%
sensitivity) of the samples from PCR-diagnosed donors within the
first 5 days of hospital admission, whereas the Siemens test
detected 113/153 (74%). On day 5 the HAT detected 41/45 (91%
sensitivity). Two samples had an endpoint greater than 11
doubling dilutions in the HAT, and required a repeat measure-
ment spanning two plates. These two samples titrated to 13
doubling dilutions (1:163,840). Unmasking the samples revealed
that both were acquired from an elderly lady with mild disease on
days 3 and 5 of her admission. The range of positive titres
detected by HAT was broad: 1–13 doubling dilutions
(1:40–1:163,840). A correlation coefficient with the Siemens test
could not be calculated as the latter has a ceiling score of 10
(Fig. 5B). A comparison of the two tests in a contingency table
with cut-off of 1:40 (first doubling dilution) for HAT, and a
score ≥ 1 for the Siemens test (as defined by the manufacturer),
showed a strong correlation between the two tests for detection of
antibodies to the RBD (P < 0.0001; two-tailed Fisher’s exact test,
Fig. 5B). Overall, 52 of the 153 samples were from 24 donors with
COVID-19 from whom repeated samples were taken on days 1, 3,
or 5 of admission. The HAT detected a rise in agglutination titre
over the first 5 days of admission in 16/24 (67%) of these patients
(Table 1, Repeat in Supplementary Table 2). Reductions in titre
were not detected.
These results showed that in the setting of hospital admission
in the UK for suspected COVID-19 disease, the HAT has an
overall sensitivity of 86% and specificity of 100% by day 5, and
frequently (67%) detected a rise in HAT titre during the first
5 days of admission. In this context, the HAT performed at least
as well as the commercially available Siemens Atellica Chemilu-
minescence assay (74%) for the detection of antibodies to the
RBD of SARS-CoV-2 spike protein. Twenty samples were
negative in both tests, but nine of these were taken on day 1 of
admission, which suggests that both tests have lower detection
levels early in the course of hospital admission, before the
antibody response has fully developed.
The O−ve blood used as indicator for this experiment was
collected into a heparin tube, and then transferred to a K2EDTA
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tube. In order to be sure that the presence of heparin in the red
cells had not altered the behaviour of the test, and to confirm the
robustness of the results, we repeated the titrations on all of the
232 samples 34 days later, with fresh O−ve red cells from a
different donor collected as usual into a K2EDTA tube. The
results are shown in Supplementary Fig. 2A–C. Specificity of
the HAT remained at 100% (none of the 79 control samples were
detected as positive at 1:40). The correlation with the previous
assay was strong (R2= 0.975), and 99% of the 232 titrations were
within one doubling dilution of the matched earlier measurement.
The slope of the correlation was 0.94 (95% CI 0.92–0.96),
significantly less than 1. This was due to a proportion of results
titrating to one doubling dilution lower titre. However, this had
only a small impact on sensitivity (81% from 86%), which was
still an improvement on the Siemens test (74%) in this context of
the first 5 days of hospital admission. A rise in HAT titre in 16/24
during the first 5 days of admission was confirmed.
HAT as a point of care test on capillary samples. The HAT is
designed to detect antibodies to the RBD starting at a serum
dilution of 1:40, and we have found that 50 µL of 1:40 dilution of
whole blood provides an optimal concentration of red blood cells
for detection by agglutination in V-bottomed 96-well plates. We
have not completed an extensive analysis of the HAT as a point of
care test. However, we have preliminary evidence that lyophilised
IH4-RBD sent to the National Institute of Immunology, New
Delhi, functions as a point of care test on capillary blood obtained
by finger prick. In Fig. 6, three positive (donors 1, 2, and 3) and
three negative (donors 4, 5, and 6) HAT results are compared to a
standard ELISA for detection of antibodies to the RBD.
Although our results clearly show that HAT represents a
simple, sensitive, robust, and very inexpensive test to detect
antibodies against RBD, further work will be needed to establish
the operating characteristics of the HAT as a point of care test on
capillary samples. As a starting point, we provide a suggested
operating procedure for capillary samples in “Methods”.
Distribution of the IH4-RBD as lyophilised protein. In order
to ship the IH4-RBD reagent efficiently, we have examined
the effects of lyophilisation and reconstitution with water. IH4-
RBD synthesised for the purpose of distribution was provided at
5 mg/mL in PBS by Absolute Antibody Ltd, Oxford. Two hun-
dred microlitre aliquots (1 mg, enough for 10,000 test wells) were
lyophilised overnight and stored at −20 °C. Aliquots were
thawed, reconstituted with 0.2 mL of double distilled water,
diluted to 1 mg/mL with 0.8 mL of PBS, and titrated against the
pre-lyophilisation material. No change in the titration occurred.
We have synthesised 1 g of IH4-RBD, sufficient for 10 million test
wells. This is available free of charge for any qualified group
anywhere in the world in aliquots of 1 mg (10,000 test wells).
Discussion
The COVID-19 pandemic has had a particularly gruelling influ-
ence on the world economy and on most populations of the
world. The appearance of such a new highly contagious virus will
probably not be a unique occurrence in the decades ahead. One of
the lessons learned is the importance of developing affordable
serological tests for detection of immune responses to SARS-
CoV-2. Commercial antibody tests are not widely available to
low- and middle-income countries, and lateral flow assays, while
offering early promise as a near-patient test, have failed to deliver
in terms of performance metrics, are expensive, and there are
concerns about significant batch-to-batch variation33. By con-
trast, the advantages of the HAT are the low cost of production of
its single reagent (~0.27 UK pence per test well, and altogether
less than 1 £/test if the costs of other consumables are taken into
Fig. 4 Operating characteristics of the HAT. A The test set of 297 randomised plasma samples was diluted 1:40 and mixed with 1:40 O−ve blood in two
columns. IH4-RBD (100 ng in 50 µL) was added to the test samples and PBS to negative control wells. The plates were incubated at room temperature for 1
h to allow the red cell pellet to form, then tilted for ~30 s to allow a teardrop to form. Complete loss of teardrop was scored as positive agglutination
(marked with a black solid-line circle). Full teardrop or partial teardrop (marked with a dotted-line circle) was scored negative. The samples in columns
were re-randomised and tested a second time 2 days later. B Contingency table showing the operating characteristics of the HAT. Source data are provided
as a Source Data file.
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account), better performance than most lateral flow devices33,
and versatility in not requiring anything other than a source of O
−ve blood (10 mL of K2EDTA blood provides enough for 8000
tests), an adjustable pipette, PBS, and a standard 96-well V-
bottomed plate.
We have demonstrated that the HAT functions as a viable test
for the presence of antibodies to the RBD of the SARS-CoV-2
spike protein in stored serum/plasma samples, using O−ve red
cells as indicators. In the formal assessment of sensitivity and
specificity, we recorded an average 90% sensitivity and 99%
specificity (likelihood ratio ~175), compared to 100% sensitivity
and 100% specificity for the Siemens Atellica Chemiluminescence
test on the same set of samples. The “positive” samples were
selected to have been taken at least 28 days after a positive PCR
test. These conditions are optimal for serological tests by allowing
time for a rise in antibodies. The sensitivity of ~90% and speci-
ficity of 99% did not reach the level of 98% for both recom-
mended by the UK MHRA19 or 99.5% for both recommended by
the Infectious Disease Society of America34. However, these
values are still consistent with a useful test in appropriate con-
texts, provided that users are fully aware of the operating char-
acteristics and interpret the results correctly. Our comparison of
the HA test with binding detected by FACS analysis suggests that
samples that fail to be detected by agglutination have very
low titre.
The sensitivity of the single point HAT can be enhanced (to
~98%) if wells with partial teardrop formation are scored as
positive. However, this improvement in sensitivity is gained at the
expense of a reduced specificity (to ~97%). If partial teardrops are
to be scored as positive in the spot test at 1:40, we recommend
obtaining confirmation for these by ELISA. Improvement in the
operating characteristics of the HAT may be possible by a sys-
tematic analysis of buffer composition and experimental condi-
tions, and is being investigated. We have deliberately kept
complexity to a minimum, and thus all dilutions were made in
standard PBS, and for the moment we recommend scoring wells
with partial teardrop formation as negative.
Titration of the HAT provides additional quantitative infor-
mation. Titrations repeated a month apart are highly repro-
ducible (Supplementary Fig. 2). Minor variations in endpoints
(+/− 1 doubling dilution) are detected between assays performed
with O−ve red cells from different donors (Supplementary
Tables 3 and 4). However, assays can be calibrated within and
between laboratories by inclusion of the WHO standard serum
20/130 now available from NIBSC UK (which titrates to 1:1280 in
the HAT), and monoclonal antibodies with defined endpoints
such as CR3022.
It is interesting that the HAT titrations actually performed a
little better than the Siemens test on 153 stored plasma samples
from donors during the first 5 days of their hospital admission
(note that symptom onset may have been several days earlier), in
whom it detected 86% (81% in the repeat) of samples from PCR-
diagnosed donors, compared to 74% for the Siemens test, and
gave 100% specificity for the sample set containing control
plasma from patients with sepsis and healthy controls. We
speculate that at this early period of the COVID-19 illness,
the immune response may be dominated by IgM that would be
expected to be particularly efficient at crosslinking the IH4-RBD
Fig. 5 Titration of the set of 232 samples in the HAT. A The collection included 32 samples from 24 critical patients, 62 samples from 48 severe,
39 samples from 32 mild, 20 single samples from healthcare workers (HCW), 54 samples from 43 patients with unrelated sepsis in the pre COVID-19 era,
and 25 samples from healthy unexposed controls. Median is indicated by a red line. DD doubling dilutions. B Comparison to Siemens result (anti-RBD) with
HAT titre by doubling dilution for 153 samples from critical, severe, mild, and HCW SARS-CoV-2 PCR positive donors. Source data are provided as a Source
Data file.
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labelled red cells. In addition, of the 24 donors who were tested
more than once in the first 5 days in hospital, the HAT detected a
rise in titre in 16 (67%). A fixed high titre was detected in a
further 4 to provide a sensitivity of 83% in these 24 cases. In
situations of high clinical suspicion, the HAT could potentially
have a place as a helpful test to support the diagnosis of COVID-
19 by detecting a rising titre of antibodies to the RBD during
hospital admission. In patients with a prior probability of a
diagnosis of COVID-19 of ~10%, the likelihood ratio of ~175 for
the HAT provides a posterior probability of ~95% for this diag-
nosis. However, it is essential that if clinicians use a rising titre in
the HAT as a diagnostic aid, they should be aware of the relatively
low sensitivity (~67%) in this context.
Finally, we show that the lyophilised IH4-RBD reagent sent to
New Delhi functioned as expected in preliminary point of care
testing on capillary samples obtained by finger prick. However,
additional evidence is needed to show that the sensitivity and
specificity of the HAT, applied as a point of care test in this way,
are comparable to the tests on stored plasma samples, as stressed
by the IDSA guideline on serological testing34. This will need to
be done in field conditions, which is planned.
In the absence of knowledge about the level of antibody that
indicates protection, the HAT should not be used to provide per-
sonal results to individuals, as discussed by the UK Royal College of
Pathologists (https://www.rcpath.org/profession/on-the-agenda/
COVID-19-testing-a-national-strategy.html). It should also not be
used as a diagnostic test in clinical practice as it is not yet validated
for this purpose. It should be most useful as an inexpensive
quantitative research method to follow seropositive individuals post
infection or post vaccination.
The technique required for applying the HAT can be learned in
a day by a trained laboratory technician, paramedic, nurse, or
doctor. We have produced 1 g of the developing IH4-RBD
reagent (enough for ten million test wells) and offer to ship
lyophilised aliquots of this material (sufficient for 10,000 tests)
anywhere in the world, free of charge, for use as a research
reagent for serological studies of COVID-19.
Methods
Sample collection and ethics. Figures 1 and 2: Control whole blood (K2EDTA) as
a source of red cells was collected from a healthy donor after informed consent.
The use was approved by HTA license 12433.
Figure 3: Pre pandemic negative controls: these samples were collected from
healthy adults in the Oxfordshire region of the UK between 2014 and 2016, ethics
approval: Oxfordshire Clinical Research Ethics Committee 08/H0606/107+5.
Positive sample set: these were convalescent plasma donors recruited by NHS
Blood and Transplant (NHSBT), ethics approval (NHSBT; RECOVERY
[Cambridge East REC (ref: 20/EE/0101)] and REMAP-CAP [EudraCT 2015-
002340-14] studies). The serum from a convalescent patient used for FACS analysis
was left-over clinical material obtained from the Virology Laboratory of the
Toulouse Hospital, where, by default, all patients gave informed consent for such
materials to be used for research purposes.
Table 1 Fifty-two samples from 24 donors who were
sampled repeatedly during the first 5 days in hospital.
Day post hospitalisation
No. Case 1 3 5
1 C2 40 160
2 C6 40 80
3 C7 0 0
4 C8 320 1280
5 C9 40 2560
6 C10 320 320
7 C23 0 160 640
8 S5 80 160
9 S6 1280 1280 2560
10 S7 80 2560
11 S12 640 1280
12 S13 0 40 320
13 S14 640 640
14 S17 2560 2560
15 S20 160 320
16 S31 40 1280
17 S41 640 1280
18 S43 40 160
19 S48 1280 2560
20 M9 0 160
21 M11 0 0 0
22 M13 0 0
23 M14 163840 163840
24 M25 40 640
25 M30 320 320
Numbers in bold indicate rising titres.
C critical, S severe, M mild.
Fig. 6 HAT as a point of care test. Capillary blood samples were obtained by Lancet. Antibodies to the RBD were detected by HAT on autologous red cells
in the sample in “Test” wells (plasma at 1:40) after addition of 100 ng/well IH4-RBD (see “Methods”). NC negative control (PBS replaces IH4-RBD), PC
positive control (20 ng/well CR3022, an anti-RBD monoclonal antibody added). In parallel, after removal of red cells, the plasma was tested in a standard
ELISA for detection of antibodies to the RBD. Low levels of antibody detected in the ELISA were sufficient to give a positive result in the HAT. Detection of
antibodies by HAT on autologous red cells obtained by finger prick has been repeated multiple times in both Oxford and Toulouse, and will be the subject
of a future report. Source data are provided as a Source Data file.
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Figures 4 and 5 and Table 1: Known COVID-19 positive samples were collated
from three ethically approved studies: Gastro-intestinal illness in Oxford: COVID
substudy [Sheffield REC, reference: 16/YH/0247]ISARIC/WHO, Clinical
Characterisation Protocol for Severe Emerging Infections [Oxford REC C,
reference 13/SC/0149], the Sepsis Immunomics project [Oxford REC C,
reference:19/SC/0296]), and by the Scotland A Research Ethics Committee (Ref:
20/SS/0028). Patients were recruited from the John Radcliffe Hospital in Oxford,
UK, between March and May 2020 by identification of patients hospitalised during
the SARS-COV-2 pandemic and recruited into the Sepsis Immunomics and
ISARIC Clinical Characterisation Protocols. Time between onset of symptoms and
sampling were known for all patients and if labelled as convalescent patients were
sampled at least 28 days from the start of their symptoms. Written informed
consent was obtained from all patients. All patients were confirmed to have a test
positive for SARS-CoV-2 using RT-PCR from an upper respiratory tract (nose/
throat) swab tested in accredited laboratories. The degree of severity was identified
as mild, severe, or critical infection according to the recommendations from the
World Health Organisation. Severe infection was defined as COVID-19 confirmed
patients with one of the following conditions: respiratory distress with RR >
30/min; blood oxygen saturation < 93%; arterial oxygen partial pressure (PaO2)/
fraction of inspired O2 (FiO2) < 300 mmHg; and critical infection was defined as
respiratory failure requiring mechanical ventilation or shock or other organ failures
requiring admission to ICU. Comparator samples from healthcare workers with
confirmed SARS-CoV-2 infection who all had mild non-hospitalised disease were
collected under the gastro-intestinal illness in Oxford: COVID substudy and
samples from patients with equivalently severe disease from non-COVID infection
were available from the Sepsis Immunomics study where patients presenting with
significantly abnormal physiological markers in the pre pandemic timeframe had
samples collected using the same methodology as that applied during the COVID
pandemic. Blood samples were collected in K2EDTA vacutainers and PBMCs were
separated from plasma using Sepmate isolation tubes (STEMCELL Technologies)
and plasma was used in the downstream HAT assay.
Figure 6: Capillary samples were collected from members of institute staff with
informed consent (New Delhi, India). The study is a part of the COVID-19 project
“IPA/2020/000077”. The project has been approved by the Institutional Human
Ethics Committee; Ref. no.–IHEC#128/20.
Cloning, expression, and purification of VHH(IH4)-RBD. The amino acid
sequence for IH4 was obtained from US Patent No US 9,879,090 B2, kindly cor-
rected by Olivier Bertrand. The codon-optimised gene encoding IH4-RBD
sequence (Fig. 1B and supplementary for the cDNA sequence) was synthesized by
Integrated DNA Technologies. The gene was cloned into the AbVec plasmid
(Genbank FJ475055) using the restriction sites AgeI and HindIII (the vector
supplied the signal sequence). This expression plasmid for IH4-RBD is available on
request. Protein was expressed in Expi293FTM cells using the manufacturer’s
protocol (Thermo Fisher). Protein supernatant was harvested on day 5/6 after
transfection, spun, and 0.22 µm filtered. The protein was affinity-purified using a
His-Trap HP column (Cytiva). Binding buffer consisted of 20 mM sodium phos-
phate, 150 mM NaCl, and 20 mM imidazole at pH 7.4 and the elution buffer of
500 mM imidazole in 1x binding buffer. Protein was concentrated using 15 mL
Vivaspin 30 kDa MWCO filter and then buffer exchanged to PBS using a 10 mL 7
kDa Zeba spin column (Thermo Fisher).
For large-scale production, the protein was synthesized by Absolute Antibody
Ltd, Oxford, using the same plasmid construct in HEK293 cells.
Monoclonal antibodies. The variable heavy and light genes of the monoclonal
antibodies CR302226, VHH72-Fc31, C12121, H11-H4-Fc29, and S30924 were syn-
thesized by Integrated DNA Technologies IDT and cloned into antibody expres-
sion vectors (GenBank FJ475055 and FJ475056). Antibody was expressed using the
ExpiCHO-S expression system according to the manufacturer’s protocol. Anti-
bodies EY6A, FI-4A, FI-3A, FD-5D, FD-11A, FN-12A, FJ-10B, FM-7B, EW-8B,
EW-9C, and FJ-1C were developed in our laboratory28.
Lyophilisation of IH4-RBD and CR3022 monoclonal antibody. For lyophilisa-
tion, 200 µL (1 mg) of IH4-RBD (5 mg/mL) and 100 µL (200 μg) CR3022 mAb
(2 mg/mL) in PBS buffer prepared in Protein Lo-Bind microcentrifuge tube (Fisher
Scientific) were frozen at −80 °C and further cooled down to −196 °C using liquid
nitrogen. Precooled samples were transferred to BenchTop K freeze dryer (VirTis)
with chamber at 49 µbar and condenser precooled to −72.5 °C. The samples were
freeze-dried for a minimum of 24 h, wrapped in Parafilm (Merck), and stored at
−20 °C. Lyophilised sample was reconstituted in the same original volume of
MilliQ water: 200 µL for IH4-RBD and 100 µL for the CR3022. The IH4-RBD was
then diluted to 1 mg/mL stock solution by addition of 800 µL of sterile PBS and
stored at 4 °C. The CR3022 was diluted 1:100 to 20 µg/mL in PBS on the day of
experiment for standard titrations.
Indirect Immunofluorescence of RBD labelled red cells (Fig. 3C). Titrations of
Mab CR3022 and a positive serum by combined HAT and FACS analysis: an
EDTA blood sample from an O−ve donor was obtained from the Toulouse blood
bank, and a 1/40 dilution in PBS was used for the assay. Serum 197, from a
convalescent COVID-19 patient, was kindly provided by Laurence Abravanel and
Jacques Izopet (Virology service, Toulouse Hospital). The HAT was performed in
100 µL/well, and pictures were taken after 60 min incubation at room temperature
and 30 s tilt of the plate. Red blood cells were then washed thrice in PFN (PBS+
2% foetal calf serum+ azide 0.2 g/L), before staining with a goat anti-human
IgGAM-FITC polyclonal secondary antibody (Jackson, Cat. No. 109-095-064, used
1/200) for 60 min on ice. Cells were then washed twice more in PFN before analysis
on a FACScalibur flow cytometer, using the Cellquest Pro software 5.2 to calculate
the mean geometric fluorescence intensity on 5000 cells within a broad FSC/SSC
rectangular gate (see Supplementary Fig. 4).
Indirect ELISA to detect SARS-CoV-2 specific IgG (Fig. 6). A standard indirect
ELISA was used to determine the SARS-CoV-2 specific IgG levels in plasma
samples. A highly purified RBD protein from SARS-CoV-2 Wuhan strain (NR-
52306, BEI Resources, USA), expressed in mammalian cells, was used to capture
IgG in the plasma samples. Briefly, ELISA plates (Nunc, MaxiSorp) were coated
with 100 µL/well of RBD antigen diluted in PBS (pH 7.4) at the final concentration
of 1 µg/mL and incubated overnight at 4 °C. Plates were washed three times with
washing buffer (0.05% Tween-20 in PBS) followed by the incubation with blocking
buffer (3% skim milk and 0.05% Tween-20 in PBS). The threefold serially diluted
heat inactivated plasma samples in dilution buffer (1% skim milk and 0.05%
Tween-20 in PBS) were added into the respective wells, followed by incubation at
room temperature for 1 h. After incubation, plates were washed, and anti-human
IgG conjugated with horseradish peroxidase (Southern Biotech) was added in each
well. After 1 h incubation, plates were washed and developed by OPD-substrate
(Sigma-Aldrich) in dark at room temperature. The reaction was stopped using 2N
HCl and the optical density (OD) was measured at 492 nm. The RBD-antigen
coated wells that were added with sample diluent alone were used as the blank. The
OD values from sample wells were plotted after subtracting the mean of OD values
obtained in the blank wells.
HAT protocol. Step by step protocol for HAT is available on Protocol Exchange
(https://doi.org/10.21203/rs.3.pex-1367/v1)35.
Equipment and reagents for HAT
(1) O−ve blood as a source of red cells collected in K2EDTA tube, diluted in
PBS to 1:20 or 1:40 as needed. Resuspend by inverting gently ~12 times.
(2) BD Contact Activated Lancet Cat. No. 366594 (2 mm × 1.5 mm).
(3) 100 µL, 20 µL pipettes, multichannel pipettes.
(4) V-bottomed 96-well plates (Greiner Bio-One, Cat. No. 651101, Microplate
96-well, PS, V-bottom, Clear, ten pieces/bag).
(5) Eppendorf tubes.
(6) K2EDTA solution (add 5 mL PBS to 10 mL K2EDTA blood collection tube
= 3.6 mg K2EDTA/mL, store at 4 °C).
(7) PBS tablets (OXOID Cat. No. BR0014G).
(8) IH4-RBD Reagent diluted 2 µg/mL in PBS. This remains active for at least
1–2 weeks stored at 4 °C.
(9) V-bottomed 96-well plates, numbered, dated, and timed (helps when timing
many plates).
(10) Positive control monoclonal antibody CR3022 diluted to 2 µg/mL in PBS.
Other reagents
Monoclonal antibody to human IgG (gamma chain specific) Clone GG-5 Sigma
Cat. No. I5885.
(1) Spot test on stored serum/plasma samples (Fig. 4).
(1) Plate out 50 µL of 1:20 serum/plasma in alternate columns 1, 3, 5, 7, 9,
and 11 (add 2.5 µL sample to 47.5 µL PBS).
(2) Add 50 µL 1:20 O−ve blood collected (so that now sample is diluted to
1:40 and red cells at ~1% v/v).
(3) Mix and transfer 50/100 µL to neighbouring columns 2, 4, 6, 8, 10, and
12 for −ve controls. The negative control is important because in rare
cases, particularly in donors who have received blood transfusions, the
sample in principle may contain antibodies to non-ABO or Rhesus D
antigens.
(4) Add 50 µL IH4-RBD reagent (2 µg/mL in PBS= 100 ng/well) to
columns 1, 3, 5, 7, 9, and 11.
(5) Add 50 µL PBS to columns 2, 4, 6, 8, 10, and 12.
(6) Inc 1 h RT.
(7) Tilt for 30 s.
(8) Photograph: with mobile phone use the zoom function to obtain a
complete field.
(9) Read as Positive=No teardrop, Negative < 1:40= partial teardrop,
Neg= complete teardrop.
(10) Two readers should read the plates independently, and disagreements
resolved by taking the lesser reading.
(11) For each batch of samples set up positive control wells containing
20–100 ng monoclonal antibody CR3022 (as in finger-prick test below).
This establishes that all of the reagents are working.
(2) Titration of stored serum/plasma samples.
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(1) Dilute samples to 1:20 in 50 µL PBS (2.5–47.5 µL) in V-bottomed plate
in rows A–H, column 1. Prepare WHO standard serum 20/130 as above
at 1:20 or CR3022 50 µL at 20 µg/mL, for calibration for each batch of
titrations. WHO standard 20/130 should titrate to ~1:1280 and 20 µg/
mL CR3022 to ~1:512.
(2) Prepare doubling dilutions with PBS across the plate columns 1–11
(1:40–1:40,960), PBS control in column 12. Eight samples can be
titrated per 96-well plate.
(3) Add 50 µL 1:40 O−ve red cells (1% v/v or 1:40 fresh EDTA O−ve blood
sample) to all wells.
(4) Add 50 µL IH4-RBD (2 µg/mL, =100 ng/well). [Note: the red cells and
IH4-RBD can be premixed and added together in either 50 or 100 µL
volume, to save a step. This variation in technique does not alter the
measured titres.]
(5) Allow red cells to settle for 1 h.
(6) Tilt plate for at least 30 s and photograph. The titre is defined by the last
well in which the teardrop fails to form. Partial teardrop regarded as
negative.
(3) Finger-prick test on capillary blood as a point of care test.
(1) Preparation: clean hands, warm digit. Prepare a plate (96-well V-
bottomed) labelled with date and time.
(2) Prick skin on outer finger pulp with disposable, single use BD or
another Lancet.
(3) Wipe away first drop of blood with sterile towel/swab.
(4) Massage second drop.
(5) Take a minimum of 5 µL blood with 20 µL pipette, mix immediately
into 20 µL K2EDTA (3.6 mg/mL/PBS) in Eppendorf. If possible, take
25 µL of blood and mix into 100 µL K2EDTA solution. Another
approach is collection of blood drops into a BD Microtainer K2E EDTA
lavender vials REF 365975 that take 250–500 µL.
(6) For 5 µL sample dilute to 200 µL with PBS (add 175 µL PBS), for 25 µL
sample dilute to 1 mL (add 975 µL PBS). Sample is now at 1:40, and the
red cells are at the correct density (~1% v/v assuming a haematocrit of
40%) to give a clear teardrop.
(7) Plate 50 µL × 3 in V-bottomed microtitre wells labelled T (Test), + (PC,
positive control), and − (NC, negative control).
(8) Add 10 µL of control anti-RBD Mab CR3022 (2 µg/mL stock in PBS, 20
ng/well) to “+“ well.
(9) Add 50 µL IH4-RBD (2 µg/mL in PBS) to “T” (Test) and “+ve“ wells,
50 µL PBS to “−ve“ well.
(10) Incubate 1 h at RT for red cells to form a pellet in the “−ve“ well.
(11) Tilt plate against a well-lit white background for ~30 s to allow teardrop
to form in “−ve“ well.
(12) The presence of antibodies to RBD is shown by loss of teardrop
formation in the “T“ and “+ve“ wells. Occasionally, a partial teardrop
forms—these wells are counted as negative.
(13) Photograph the plate to record the results with the date and time.
Results can be reviewed and tabulated later. Taking picture from a
distance and using the zoom function helps to take a clear picture of all
wells in a 96-well plate.
(14) The negative (PBS) control should be done on every sample for
comparison. The Positive control induced by CR3022 is used to check
that all the reagents are working, and that the glycophorin epitope
recognised by VHH(IH4) is present on the red cells. Absence of the IH4
epitope should be very rare 6. For setting up cohorts a positive control
on every sample is therefore not necessary but should be included in
every batch of samples.
(15) If a 25 µL sample of blood was taken from the finger prick there should
be 850 µL of the 1:40 diluted blood left. The red cells can be removed
and a preparation of 1:40 O−ve red cells used as above to titrate the
sample. In principle, the autologous red cells could be washed ×3,
resuspended in the same volume of PBS, and used as indicators for the
titration, however we have not attempted to do this. The supernatant is
1:40 plasma that can be used in confirmatory ELISA or other tests.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All the data that support the findings of this study are available in the accompanying
Source Data file. Any other relevant data are available from the authors upon reasonable
request.
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